CTOs on the Move

Michigan Medicine

www.med.umich.edu

 
Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.med.umich.edu
  • 1500 E Medical Center Dr
    Ann Arbor, MI USA 48109
  • Phone: 734.936.4000

Executives

Name Title Contact Details

Similar Companies

Avectas

Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.

EYELA Tokyo Rikakikai Co

EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EV Biologics

EV Biologics is a biotechnology company that is developing extracellular vesicles (EVs) to create diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions.

Advitech

Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beigene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.